Scancell Holdings plc
AIM:SCLP Voorraadrapport
Marktkapitalisatie: UK£130.1m
Scancell Holdings Toekomstige groei
Future criteriumcontroles 0/6 De omzet en winst van Scancell Holdings zullen naar verwachting dalen met respectievelijk 25% en 22.4% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 23.1% per jaar.
Belangrijke informatie
-23.1%
Groei van de winst per aandeel
Biotechs winstgroei 37.3% Inkomstengroei -25.0% Toekomstig rendement op eigen vermogen n/a Dekking van analisten Low
Laatst bijgewerkt 17 Oct 2024
Recente toekomstige groei-updates
Price target decreased by 12% to UK£0.23 Dec 01
Price target increased by 8.6% to UK£0.27 Jan 25
Toon alle updates Scancell Holdings plc Announces CEO Changes
Scancell Holdings plc, Annual General Meeting, Oct 25, 2024 Oct 01
Scancell Holdings plc to Report Fiscal Year 2024 Results on Sep 24, 2024 Sep 18
New minor risk - Financial data availability Sep 16 Scancell Holdings plc Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial
Scancell Holdings plc Announces That A Group of Medical Oncologists in the Field of Melanoma Treatment Reviewed and Strengthened Scancell's Plan for A Phase 2/3 Registration Study Following Completion of the Ongoing Scope Study Jul 24
New minor risk - Share price stability Jul 19
Scancell Holdings plc Appoints Florian Reinaud to the Board Jul 10
New minor risk - Shareholder dilution Jul 07
New minor risk - Market cap size Jun 12
New minor risk - Market cap size Apr 17
Scancell Holdings plc Appoints Sath Nirmalananthan to the Board Mar 15
Scancell Holdings plc Directorate and Executive Changes Changes Feb 05
New minor risk - Share price stability Jan 31
Scancell Holdings plc to Report First Half, 2024 Results on Jan 30, 2024 Jan 26
Scancell Holdings plc Announces Update on SCOPE Trial Jan 18 Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £11.897217 million. Dec 20
Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £12.672161 million. Dec 02
Price target decreased by 12% to UK£0.23 Dec 01 Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £8.08 million. Dec 01
New major risk - Negative shareholders equity Nov 02
Scancell Holdings plc, Annual General Meeting, Nov 29, 2023 Nov 01
Scancell Holdings plc to Report Q4, 2023 Results on Oct 12, 2023 Oct 05
Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free Sep 29
Scancell Holdings plc Announces Positive Data from the First Stage in its Phase 2 Scope Trial with SCIB1 Cancer Vaccine Delivered by Needle Free Injection for Advanced Melanoma Sep 20
Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets SCIB1/iSCIB-1+ and Modi-1 Sep 14
Scancell Holdings plc Announces Appointment of Dr Mandeep Sehmi as Head of Business Development Sep 08
Scancell Appoints Sath Nirmalananthan as CFO Aug 29
New minor risk - Financial data availability Jul 28
New minor risk - Market cap size Jul 17
Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1 Jul 12
Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1 Jul 11
Scancell Holdings plc Announces Positive Response in Covidity Trial Feb 13
Scancell Holdings plc Announces Executive Changes Feb 01
Price target increased by 8.6% to UK£0.27 Jan 25
Scancell Holdings plc to Report First Half, 2023 Results on Jan 25, 2023 Jan 18
Less than half of directors are independent Nov 16
Scancell Holdings plc Announces First Patient Dosed in Expansion Phase of Modify Nov 01
Scancell Holdings plc, Annual General Meeting, Nov 21, 2022 Oct 30
Is Scancell Holdings (LON:SCLP) A Risky Investment? Oct 29
Scancell Holdings plc Announces Board Changes Oct 26
Scancell Holdings plc Announces First Patient Dosed in Cohort 2 of the ModiFY Phase 1 Clinical Trial Aug 17
Scancell Holdings plc to Produce TCB Antibodies Jun 23
Scancell Holdings plc Announces an Update to the Phase 2 Scope Clinical Trial Jun 15
Scancell Holdings plc Announces the Enrolment and Treatment of the First Patient in Its Multicentre Modi-1 Clinical Trial (Modify) At Imperial College London, Hammersmith Hospital Jun 13
Less than half of directors are independent Apr 27
Scancell Holdings plc Announces Modi-1 Phase 1/2 Trial Open for Recruitment Apr 11
Scancell Holdings plc Announces Update on Covidity Clinical Trial Mar 29
Is Scancell Holdings (LON:SCLP) A Risky Investment? Feb 10
Scancell Holdings plc Announcedsfurther Progress of the Phase 1 Covidity Clinical Trial Being Conducted At the University of Cape Town (UCT) Lung Institute in South Africa Jan 31
Scancell Holdings plc Announces the UK's Medicines and Healthcare Products Regulatory Authority Approves the Clinical Trial Application to Initiate the First-in-Human Phase I/II Clinical Study of Modi-1 Aug 27
CEO & Director Clifford Holloway has left the company Aug 04
Scancell Holdings plc Announces COVIDITY Phase 1 Clinical Trial Planned in South Africa and UK for Novel Bivalent COVID-19 Vaccine Jun 22
New 90-day high: UK£0.21 Feb 15
Scancell Holdings plc Announces an Update on its SCIB2 Clinical Development Partnership with Cancer Research UK Feb 03
Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like Dec 28
Scancell Holdings plc Appoints Gillies O'Bryan-Tear as Chief Medical Officer and Robert Miller as Medical Director Nov 18
Scancell Holdings plc to Report Fiscal Year 2020 Results on Oct 16, 2020 Oct 05
Cobra Biologics and Scancell Holdings plc Announces Collaboration to Manufacture COVID-19 Vaccine Oct 02 Scancell Holdings plc announced that it expects to receive £1.3 million in funding from Cherwell Capital plc, Oxford Technology Management Limited, Oxford Capital Partners LLP, Seneca Partners Limited, Octopus Investments Limited
Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £9.007417 million. Aug 12
Winst- en omzetgroeiprognoses AIM:SCLP - Toekomstschattingen van analisten en financiële gegevens uit het verleden (GBP Millions ) Datum Inkomsten Inkomsten Vrije kasstroom Geldmiddelen uit operationele activiteiten Gem. Aantal analisten 4/30/2027 N/A N/A -15 N/A 1 4/30/2026 N/A -10 -14 -6 3 4/30/2025 2 -13 -11 -8 3 4/30/2024 N/A -6 -16 -16 N/A 1/31/2024 N/A -8 -13 -13 N/A 10/31/2023 N/A -10 -11 -11 N/A 7/31/2023 3 -11 -9 -9 N/A 4/30/2023 5 -12 -8 -8 N/A 1/31/2023 5 -12 -9 -9 N/A 10/31/2022 5 -13 -11 -10 N/A 7/31/2022 3 -9 -11 -10 N/A 4/30/2022 N/A -5 -11 -10 N/A 1/31/2022 N/A -6 -11 -10 N/A 10/31/2021 N/A -8 -11 -9 N/A 7/31/2021 N/A -12 -10 -8 N/A 4/30/2021 N/A -15 -9 -8 N/A 1/31/2021 N/A -11 -7 -7 N/A 10/31/2020 N/A -7 -6 -5 N/A 7/31/2020 N/A -6 -5 -5 N/A 4/30/2020 N/A -6 -5 -5 N/A 1/31/2020 N/A -5 -5 -5 N/A 10/31/2019 N/A -5 -6 -6 N/A 7/31/2019 N/A -5 -6 -6 N/A 4/30/2019 N/A -6 -7 -7 N/A 1/31/2019 N/A -6 -6 -6 N/A 10/31/2018 N/A -5 -6 -6 N/A 7/31/2018 N/A -5 -5 -5 N/A 4/30/2018 N/A -4 -4 -4 N/A 1/31/2018 N/A -4 N/A -4 N/A 10/31/2017 N/A -4 N/A -4 N/A 7/31/2017 N/A -4 N/A -4 N/A 4/30/2017 N/A -4 N/A -4 N/A 1/31/2017 N/A -3 N/A -3 N/A 10/31/2016 N/A -3 N/A -3 N/A 7/31/2016 N/A -3 N/A -3 N/A 4/30/2016 N/A -3 N/A -2 N/A 1/31/2016 N/A -2 N/A -2 N/A 10/31/2015 N/A -2 N/A -3 N/A 7/31/2015 N/A -2 N/A -3 N/A 4/30/2015 N/A -2 N/A -3 N/A 1/31/2015 N/A -2 N/A -2 N/A 10/31/2014 N/A -2 N/A -2 N/A 7/31/2014 N/A -2 N/A -2 N/A 4/30/2014 N/A -2 N/A -2 N/A
Meer tonen
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat SCLP de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat SCLP de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat SCLP de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van SCLP zal naar verwachting de komende 3 jaar dalen ( -25% per jaar).
Hoge groei-inkomsten: De omzet van SCLP zal naar verwachting de komende 3 jaar dalen ( -25% per jaar).
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SCLP naar verwachting over 3 jaar hoog zal zijn
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}
